vs
Martin Marietta Materials（MLM）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
硕腾的季度营收约是Martin Marietta Materials的1.7倍（$2.3B vs $1.4B），Martin Marietta Materials净利率更高（111.1% vs 26.6%，领先84.5%），Martin Marietta Materials同比增速更快（17.0% vs 2.9%），过去两年硕腾的营收复合增速更高（-2.1% vs -12.1%）
马丁·玛丽埃塔材料公司是美国大型集料及重型建筑材料供应商，业务覆盖美国26个州、加拿大及加勒比地区，主要为道路、人行道、地基等各类基建项目提供所需原材料。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
MLM vs ZTS — 直观对比
营收规模更大
ZTS
是对方的1.7倍
$1.4B
营收增速更快
MLM
高出14.1%
2.9%
净利率更高
MLM
高出84.5%
26.6%
两年增速更快
ZTS
近两年复合增速
-12.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $2.3B |
| 净利润 | $1.5B | $601.0M |
| 毛利率 | 22.8% | 71.7% |
| 营业利润率 | 11.9% | — |
| 净利率 | 111.1% | 26.6% |
| 营收同比 | 17.0% | 2.9% |
| 净利润同比 | — | -0.2% |
| 每股收益（稀释后） | — | $1.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLMZTS
| Q1 26 | $1.4B | $2.3B | ||
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.8B | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.9B | $2.4B | ||
| Q2 24 | $1.8B | $2.4B |
净利润MLMZTS
| Q1 26 | $1.5B | $601.0M | ||
| Q4 25 | $279.0M | $603.0M | ||
| Q3 25 | $414.0M | $721.0M | ||
| Q2 25 | $328.0M | $718.0M | ||
| Q1 25 | $116.0M | $631.0M | ||
| Q4 24 | $293.0M | $581.0M | ||
| Q3 24 | $363.0M | $682.0M | ||
| Q2 24 | $294.0M | $624.0M |
毛利率MLMZTS
| Q1 26 | 22.8% | 71.7% | ||
| Q4 25 | 35.0% | 70.2% | ||
| Q3 25 | 33.1% | 71.5% | ||
| Q2 25 | 30.0% | 73.6% | ||
| Q1 25 | 24.8% | 72.0% | ||
| Q4 24 | 30.0% | 69.5% | ||
| Q3 24 | 31.7% | 70.6% | ||
| Q2 24 | 29.3% | 71.7% |
营业利润率MLMZTS
| Q1 26 | 11.9% | — | ||
| Q4 25 | 24.6% | 31.9% | ||
| Q3 25 | 27.4% | 37.0% | ||
| Q2 25 | 25.3% | 36.7% | ||
| Q1 25 | 14.3% | 36.5% | ||
| Q4 24 | 24.4% | 31.6% | ||
| Q3 24 | 25.9% | 36.6% | ||
| Q2 24 | 22.6% | 33.0% |
净利率MLMZTS
| Q1 26 | 111.1% | 26.6% | ||
| Q4 25 | 24.5% | 25.3% | ||
| Q3 25 | 22.4% | 30.0% | ||
| Q2 25 | 18.1% | 29.2% | ||
| Q1 25 | 8.6% | 28.4% | ||
| Q4 24 | 18.0% | 25.1% | ||
| Q3 24 | 19.2% | 28.6% | ||
| Q2 24 | 16.7% | 26.4% |
每股收益（稀释后）MLMZTS
| Q1 26 | — | $1.42 | ||
| Q4 25 | $4.59 | $1.37 | ||
| Q3 25 | $6.85 | $1.63 | ||
| Q2 25 | $5.43 | $1.61 | ||
| Q1 25 | $1.90 | $1.41 | ||
| Q4 24 | $4.87 | $1.29 | ||
| Q3 24 | $5.91 | $1.50 | ||
| Q2 24 | $4.76 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | — |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $11.3B | — |
| 总资产 | $20.5B | — |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资MLMZTS
| Q1 26 | $273.0M | — | ||
| Q4 25 | $67.0M | — | ||
| Q3 25 | $57.0M | $2.1B | ||
| Q2 25 | $225.0M | $1.4B | ||
| Q1 25 | $101.0M | $1.7B | ||
| Q4 24 | $670.0M | $2.0B | ||
| Q3 24 | $52.0M | $1.7B | ||
| Q2 24 | $109.0M | $1.6B |
总债务MLMZTS
| Q1 26 | $0 | — | ||
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.5B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.3B | — |
股东权益MLMZTS
| Q1 26 | $11.3B | — | ||
| Q4 25 | $10.0B | $3.3B | ||
| Q3 25 | $9.7B | $5.4B | ||
| Q2 25 | $9.4B | $5.0B | ||
| Q1 25 | $9.1B | $4.7B | ||
| Q4 24 | $9.5B | $4.8B | ||
| Q3 24 | $9.2B | $5.2B | ||
| Q2 24 | $8.8B | $5.0B |
总资产MLMZTS
| Q1 26 | $20.5B | — | ||
| Q4 25 | $18.7B | $15.5B | ||
| Q3 25 | $18.7B | $15.2B | ||
| Q2 25 | $18.1B | $14.5B | ||
| Q1 25 | $17.7B | $14.1B | ||
| Q4 24 | $18.2B | $14.2B | ||
| Q3 24 | $16.5B | $14.4B | ||
| Q2 24 | $16.3B | $14.2B |
负债/权益比MLMZTS
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $227.0M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 40.4% | — |
| 现金转化率经营现金流/净利润 | 0.15× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MLMZTS
| Q1 26 | $227.0M | — | ||
| Q4 25 | $629.0M | $893.0M | ||
| Q3 25 | $551.0M | $938.0M | ||
| Q2 25 | $387.0M | $486.0M | ||
| Q1 25 | $218.0M | $587.0M | ||
| Q4 24 | $686.0M | $905.0M | ||
| Q3 24 | $600.0M | $951.0M | ||
| Q2 24 | $1.0M | $502.0M |
自由现金流MLMZTS
| Q1 26 | — | — | ||
| Q4 25 | $424.0M | $732.0M | ||
| Q3 25 | $361.0M | $805.0M | ||
| Q2 25 | $208.0M | $308.0M | ||
| Q1 25 | $-15.0M | $438.0M | ||
| Q4 24 | $453.0M | $689.0M | ||
| Q3 24 | $317.0M | $784.0M | ||
| Q2 24 | $-138.0M | $370.0M |
自由现金流率MLMZTS
| Q1 26 | — | — | ||
| Q4 25 | 37.2% | 30.7% | ||
| Q3 25 | 19.6% | 33.5% | ||
| Q2 25 | 11.5% | 12.5% | ||
| Q1 25 | -1.1% | 19.7% | ||
| Q4 24 | 27.8% | 29.7% | ||
| Q3 24 | 16.8% | 32.8% | ||
| Q2 24 | -7.8% | 15.7% |
资本支出强度MLMZTS
| Q1 26 | 40.4% | — | ||
| Q4 25 | 18.0% | 6.7% | ||
| Q3 25 | 10.3% | 5.5% | ||
| Q2 25 | 9.9% | 7.2% | ||
| Q1 25 | 17.2% | 6.7% | ||
| Q4 24 | 14.3% | 9.3% | ||
| Q3 24 | 15.0% | 7.0% | ||
| Q2 24 | 7.9% | 5.6% |
现金转化率MLMZTS
| Q1 26 | 0.15× | — | ||
| Q4 25 | 2.25× | 1.48× | ||
| Q3 25 | 1.33× | 1.30× | ||
| Q2 25 | 1.18× | 0.68× | ||
| Q1 25 | 1.88× | 0.93× | ||
| Q4 24 | 2.34× | 1.56× | ||
| Q3 24 | 1.65× | 1.39× | ||
| Q2 24 | 0.00× | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLM
暂无分部数据
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
